In The News

MeRes100 BRS, the first bioresorbable vascular matrix to treat coronary artery disease

MeRes100 BRS, the first bioresorbable vascular matrix to treat coronary artery disease

MeRes100 BRS - the first thin-tip sirolimus releasing bioresorbable vascular matrix - shows positive long-term safety consistent with low cardiac event rates and zero matrix stent thrombosis for patients with coronary artery disease   

LONDON, July 12, 2019 / PRNewswire / - Meril's MeRes100 recently approved by the EC, used for the treatment of de novo coronary artery lesions , has demonstrated zero matrix thrombosis and a very low event rate Severe adverse cardiac 1.87% at three years, as shown in MeRes-1 and 1.61% in MeRes-1 Extend at two years.

"First-generation bio-absorbable matrices have not shown the most favorable long-term results. MeRes100, a next-generation bio-absorbable matrix, has been developed with a reduced thickness tip, an improved profile for better deliverability, faster degradation and matrix thrombosis possibly lower, "said the chief investigator of the MeRes-1 trial, Dr. Ashok Seth, president of the Fortis Escorts Heart Institute in New Delhi, India. 

MeRes-1 

The three-year long-term follow-up data of the first MeRes-1 study conducted in humans, published in EuroIntervention 1, demonstrated the high efficacy of MeRes100 BRS with multimodality imaging at two years, including:  

Low late lumen loss (0.24 ± 0.34mm) with quantitative coronary angiography (QCA) Nearly complete strut coverage (99.24%) with optical coherence tomography (OCT) Sustained medium flow area and percentage volume obstruction very low (7.5%) with intravascular ultrasound (IVUS)

MeRes-1 Extend 

The two-year data from this global study, which recruited patients from Brazil, Europe and Asia, demonstrated a relatively low late lumen loss (0.18 ± 0.31mm) with a serial QCA analysis at six months follow-up. suggests high efficacy in inhibiting NIH in late follow-up, and an area of ​​sustained mean flow and almost complete strut coverage (97.9 ± 3.7) shown in an OCT subset analysis at six months.2

"The encouraging results of MeRes100 BRS are changing the way we currently see bio-absorbable matrices," said Dr. Ashok Thakkar, director of Clinical Research at Meril Life Sciences. "We want to continue developing the clinical evidence of this next-generation technology against a drug-eluting stent in a random environment in due course."  

About MeRes100 BRS MeRes100 BRS, a product designed and manufactured in India by Meril Life Sciences, is a bio-absorbable vascular matrix system with a low strut thickness of 100 microns that is naturally reabsorbed into the artery within a period of 2 to 3 years , leaving the glass in its form and real nature.   

About Meril Founded in 2006, Meril is a global medical device company dedicated to innovating, designing and developing new, clinically relevant and cutting-edge vascular intervention devices, orthopedic implants, in-vitro diagnostics, endo-surgery and ENT products. For more information about Meril, visit https://www.merillife.com/. Follow Meril Life Sciences on LinkedIn here.

References  1. Ashok S, et al . Three-year clinical and two-year multimodality imaging outcomes of a thin-strut sirolimus-eluting bioresorbable vascular scaffold: MeRes-1 trial. EuroIntervention . 2019; 15: 1–9 2. Abizaid A. MeRes-1 Extend study: Imaging and two-year clinical outcomes of thin strut sirolimus-eluting bioresorbable vascular scaffold in patients with coronary artery disease. Presented at EuroPCR 2019.


READ FULL ARTICLE HERE